BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia

Blood Cancer Journal

Volumn 3, Issue 7, 2013, Pages

  Da Costa, D ^a   Agathanggelou, A ^a   Perry, T ^a   Weston, V ^a   Petermann, E ^a   Zlatanou, A ^a   Oldreive, C ^a   Wei, W ^a   Stewart, G ^a   Longman, J ^a   Smith, E ^a   Kearns, P ^a,c   Knapp, S ^b   Stankovic, T ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

ALL; BET proteins; Inhibitor

Indexed keywords

STEM CELL FACTOR; TRANSCRIPTION FACTOR T BET;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER PROGNOSIS; CELL CYCLE ARREST; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DNA REPLICATION; DOWN REGULATION; IN VITRO STUDY; PEDIATRIC B PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA; PROTEIN STABILITY;

EID: 84880894039     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.24     Document Type: Article

References (45)

1. Campana D. Molecular determinants of treatment response in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2008; 2008: 366-373.
2. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol 2009; 46: 100-106.
3. Mitchell C, Payne J, Wade R, Vora A, Kinsey S, Richards S et al. The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99. Br J Haematol 2009; 146: 424-436.
4. Bhatia S. Late effects among survivors of leukemia during childhood and adolescence. Blood Cells Mol Dis 2003; 31: 84-92. (Pubitemid 36802248)
5. Kaste SC, Jones-Wallace D, Rose SR, Boyett JM, Lustig RH, Rivera GK. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia 2001; 15: 728-734. (Pubitemid 32492695)
6. Kuiper RP, Waanders E, J van der Velden VH, van Reijmersdal SV, Venkatachalam R, Scheijen B et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL et al. Leukemia 2010; 24: 1258-1264.
7. Waanders E, van der Velden VHJ, van der Schoot CE, van Leeuwen FN, van Reijmersdal SV, de Haas V et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 2010; 25: 254-258.
8. Palmi C, Vendramini E, Silvestri D, Longinotti G, Frison D, Cario G et al. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia 2012; 26: 2245-2253.
9. Hunger SP, Raetz EA, Loh ML, Mullighan CG. Improving outcomes for high-risk ALL: translating new discoveries into clinical care. Pediatr Blood Cancer 2011; 56: 984-993.
10. Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol 2009; 144: 147-156.
11. Lee-Sherick AB, Linger RM, Gore L, Keating AK, Graham DK. Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol 2010; 151: 295-311.
12. Szczepań ski T, Harrison CJ, van Dongen JJ. Genetic aberrations in paediatric acute leukaemias and implications for management of patients. Lancet Oncol 2010; 11: 880-889.
13. Marston E, Weston V, Jesson J, Maina E, McConville C, Agathanggelou A et al. Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response. Blood 2009; 113: 117-126.
14. Weston VJ, Austen B, Wei W, Marston E, Alvi A, Lawson S et al. Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-kappaB survival pathway signaling. Blood 2004; 104: 1465-1473. (Pubitemid 39166526)
15. He N, Chan CK, Sobhian B, Chou S, Xue Y, Liu M et al. Human polymerase- associated factor complex (PAFc) connects the super elongation complex (SEC) to RNA polymerase II on chromatin. Proc Natl Acad Sci USA 2011; 108: E636-E645.
16. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-528.
17. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O et al. Selective inhibition of BET bromodomains. Nature 2010; 468: 1067-1073.
18. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
19. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011; 108: 16669-16674.
20. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011; 478: 529-533.
21. Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012; 120: 2843-2852.
22. Smyth Gordon K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology 2004; 3: 1544-6115.
23. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression pro-les. Proc Natl Acad Sci USA 2005; 102: 15545-15550. (Pubitemid 41528093)
24. Petta TB, Nakajima S, Zlatanou A, Despras E, Couve-Privat S, Ishchenko A et al. Human DNA polymerase iota protects cells against oxidative stress. EMBO J 2008; 27: 2883-2895.
25. Cohen SM, Chastain 2nd PD, Rosson GB, Groh BS, Weissman BE, Kaufman DG et al. BRG1 co-localizes with DNA replication factors and is required for efficient replication fork progression. Nucleic Acids Res 2010; 38: 6906-6919.
26. Lee AY, Chiang CM. Chromatin adaptor Brd4 modulates E2 transcription activity and protein stability. J Biol Chem 2009; 284: 2778-2786.
27. Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, Popov N et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009; 15: 67-78.
28. Maruyama T, Farina A, Dey A, Cheong J, Bermudez VP, Tamura T et al. A mammalian bromodomain protein, brd4, interacts with replication factor C and inhibits progression to S phase. Mol Cell Biol 2002; 22: 6509-6520.
29. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M et al. Non-transcriptional control of DNA replication by c-Myc. Nature 2007; 448: 445-451. (Pubitemid 47123512)
30. Tissing WJE, Meijerink JPP, den Boer ML, Pieters R. Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia 2003; 17: 17-25. (Pubitemid 36175883)
31. Laane E, Tamm KP, Buentke E, Ito K, Kharaziha P, Oscarsson J et al. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ 2009; 16: 1018-1029.
32. Lauten M, Matthias T, Stanulla M, Beger C, Welte K, Schrappe M. Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia 2002; 16: 1437-1442.
33. Gruber G, Carlet M, Türtscher E, Meister B, Irving JAE, Ploner C. Levels of glucocorticoid receptor and its ligand determine sensitivity and kinetics of glucocorticoid-induced leukemia apoptosis. Leukemia 2009; 23: 820-823.
34. Lauten M, Schrauder A, Kardinal C, Harbott J, Welte K, Schlegelberger B. Unsupervised proteome analysis of human leukaemia cells identifies the Valosin-containing protein as a putative marker for glucocorticoid resistance. Leukemia 2006; 20: 820-826.
35. Tissing WJ, den Boer ML, Meijerink JP, Menezes RX, Swagemakers S, van der Spek PJ et al. Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood 2007; 109: 3929-3935. (Pubitemid 46646638)
36. Roy A, Bradburn M, Moorman AV, Burrett J, Love S, Kinsey SE et al. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol 2005; 129: 35-44. (Pubitemid 40524049)
37. Mitchell C, Payne J, Wade R, Burrett J, Love S, Kinsey SE et al. The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99. Br J Haematol 2009; 146: 424-436.
38. Lauten M, Möricke A, Beier R, Zimmermann M, Stanulla M, Meissner B et al. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica 2012; 97: 1048-1056.
39. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003; 101: 3809-3817. (Pubitemid 36857851)
40. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005; 129: 734-745. (Pubitemid 40904523)
41. Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL et al. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study - Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 2013; 31: 1202-1210.
42. Mollereau B, Perez-Garijo A, Bergmann A, Miura M, Gerlitz O, Ryoo HD et al. Compensatory proliferation and apoptosis-induced proliferation: a need for clarification. Cell Death Differ 2013; 20: 181.
43. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 2011; 17: 860-866.
44. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-1108. (Pubitemid 351818697)
45. Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA et al. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 2004; 103: 4659-4665. (Pubitemid 38745999)